2024-10-20 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops, manufactures, and markets prescription medicines. 

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):**
    * **Cumulative Return (LLY):** 884.77%
    * **Cumulative Return (VOO):** 137.88%
    * **Difference:** 746.89%
    * **Relative Divergence:** 92.67% (Indicating LLY is significantly outperforming VOO in the long term, at the 90th percentile of its historical range)

2. **Recent Price Movement:**
    * **Closing Price:** $917.97
    * **5-Day Moving Average:** $918.87
    * **20-Day Moving Average:** $907.78
    * **60-Day Moving Average:** $900.17
    * **Interpretation:**  The stock is currently trading slightly above its 5-day moving average, suggesting a short-term bullish trend. However, the stock is trending upward within its 20-day and 60-day moving averages, indicating a longer-term positive trajectory.

3. **Technical Indicators:**
    * **RSI:** 65.14 (Indicates the stock is in the overbought territory but not significantly so.)
    * **PPO:** 0.21 (Suggests that the price momentum is positive and the stock is likely to continue its upward trend.)
    * **Delta_Previous_Relative_Divergence:** -1.59 (Short-term bearish divergence, suggesting a potential slowdown in the upward momentum.)
    * **Expected_Return:** 47.88% (Indicates a potential long-term (2+ years) outperformance compared to the S&P 500.)

4. **Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2023-05-09 | 1.96 | 8.31 B$ |

**Analysis:**

Eli Lilly has been experiencing strong revenue growth, consistently exceeding analysts' expectations. Notably, the latest earnings report (2024-08-08) showed a significant increase in EPS, reflecting the company's continued success in its core pharmaceutical business. Despite the slightly bearish short-term divergence indicated by the Delta_Previous_Relative_Divergence, the strong earnings and overall positive momentum suggest a promising future for LLY.

**5. News & Recent Issues:**

**Recent Market Outlook:**
* Eli Lilly has been consistently receiving positive market sentiment due to its strong drug pipeline and revenue growth.
* The company's successful launches of new drugs like Mounjaro for diabetes and Alzheimer's treatment candidates are major contributing factors to its market performance.
* Investor confidence remains high in LLY, with analysts expecting further growth in the coming quarters.

**Analyst Opinions:**
* Most analysts have a "Buy" or "Strong Buy" rating on LLY, with an average price target exceeding $1000.
* Investors are optimistic about LLY's long-term growth potential, particularly due to its strong patent protection for its key drugs and ongoing research and development efforts.

**Performance Highlights:**
* LLY's share price has gained significantly over the past year, outperforming the overall market. 
* The company has been recognized for its commitment to innovation and its strong financial performance. 

**6. Overall Analysis:**

Eli Lilly and Co (LLY) presents a compelling investment opportunity, showing robust growth potential and a strong track record of exceeding expectations. Despite short-term indicators suggesting a potential slowdown, the long-term outlook remains bullish, with the company's innovative pipeline and market leadership position offering substantial upside potential. The high expected return and continued positive analyst sentiment further support the case for investing in LLY for the long term.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Always consult with a qualified financial advisor before making any investment decisions.
